Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today reported its financial results for the second quarter 2011. Onyx reported a non-GAAP net loss of $27.2 million, or $0.43 per diluted share, for the second quarter 2011 compared to a non-GAAP net income of $2.9 million, or $0.05 per diluted share, for the same period in 2010. Non-GAAP net loss excludes, among other items, adjustments to contingent consideration expense in connection with Onyx's acquisition of Proteolix Inc., or Proteolix; employee stock-based compensation expense; lease termination exit costs, non-cash imputed interest expense related to the application of Accounting Standards Codification ("ASC") 470-20 and charges associated with the restructuring of Onyx's development, collaboration, option and license agreement with S*BIO Pte Ltd., or S*BIO.

"The quarter was marked by continued progress across our product portfolio," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "Approved for the treatment of liver cancer and kidney cancer, Nexavar delivered another quarter of solid operating performance driven by strong growth in the Asia Pacific region. With five late-stage clinical trials expected to read-out by the end of 2012, Nexavar is poised to penetrate existing and new markets."  Dr. Coles continued, "Our Phase 3 confirmatory trials with carfilzomib, ASPIRE and FOCUS, are well underway.  Importantly, we are ramping up preparation for the commercialization of carfilzomib, in anticipation of a potential U.S. approval next year."

On a GAAP basis, Onyx reported a net loss of $54.5 million, or $0.86 per diluted share, for the second quarter 2011 compared to a net loss of $97.2 million, or $1.55 per diluted share, for the same period in 2010. A description of the non-GAAP calculations and reconciliation to co
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
4. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
5. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
6. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Inc. (OTC.QB: VGEN), a cancer immunotherapy development company, today ... Co-founder, President, Chief Executive Officer and current Director, ... of the Board. Mr. Tussing replaces Benjamin S. ... and his role as Chairman and a member of ... for the President of the United States ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... the "Will Theranos Turn the Lab Industry Upside ... has received much praise along with a healthy dose ... public" with their potentially disruptive laboratory solution. Behind all ... Has Theranos scaled microfluidic technology across a comprehensive ...
(Date:5/4/2015)... -- Luminex Corporation (NASDAQ: LMNX ) today announced financial ... and operating highlights include the following: , Consolidated ... over the first quarter of 2014. , First quarter ... the first quarter of 2014. , Consolidated gross profit ... , GAAP net income for the first quarter was ...
Breaking Medicine Technology:Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 2Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board 3Will Theranos Turn the Lab Industry Upside Down? 2Luminex Corporation Reports First Quarter 2015 Results 2Luminex Corporation Reports First Quarter 2015 Results 3Luminex Corporation Reports First Quarter 2015 Results 4Luminex Corporation Reports First Quarter 2015 Results 5Luminex Corporation Reports First Quarter 2015 Results 6Luminex Corporation Reports First Quarter 2015 Results 7Luminex Corporation Reports First Quarter 2015 Results 8Luminex Corporation Reports First Quarter 2015 Results 9Luminex Corporation Reports First Quarter 2015 Results 10Luminex Corporation Reports First Quarter 2015 Results 11
... with active moderate to severe rheumatoid arthritis (RA) inadequately ... (Humira ® ) and who were actively switched to ... at week 10, and sustained response through week 26 ... from the RESTART study were presented for the first ...
... PharmaNova, Inc., of Victor, NY , announced today that ... of $500,000 under the Qualifying Therapeutic Discovery Project (QTDP), which ... and Affordable Care Act of 2010. In July, PharmaNova applied ... NovaSperse(SM) -based nanoparticulate products. NovaSperse(SM) ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative 2
(Date:5/5/2015)... AR (PRWEB) May 05, 2015 ... is collaborating with American Eagle Outfitters on a ... enhance natural beauty. , For the debut ... with Aerie by American Eagle ; the ... brand's body-image campaign, called "Aerie REAL," uses models ...
(Date:5/5/2015)... May 05, 2015 May is National Osteoporosis ... Institute for Better Bone Health . Founded by Charles ... to educate both consumers and physicians about the latest advances ... bone health. , According to a study recently published by ... Americans are affected by osteoporosis and low bone mass. This ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they ... with Ed Begley Jr., airing via Discovery Channel 3rd ... segment will focus on NovaSom, a leader in Obstructive ... their AccuSom® home sleep test, which is the only ... support and next-day test results and interpretation. , ...
(Date:5/5/2015)... 05, 2015 Care Logistics ... called “Medicare Breakeven Challenges? A Model to ... ,     Formulas for two critical ... but should be ,     A model ... space” and ensures sustained efficient operations , ...
(Date:5/5/2015)... Crawford Technologies announced today it has been awarded ... of the Business Marketing Association (BMA) for the redesign ... was presented to the CrawfordTech marketing team on Friday, May ... over 300 people in attendance. , “The launch of the ... a shift in focus for how our company communicates our ...
Breaking Medicine News(10 mins):Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 3Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Care Logistics Publishes a New Hospital Guidebook for Achieving Medicare Breakeven 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 2Health News:Crawford Technologies Awarded BMA’s ‘2015 Gold Key Award’ for Innovative Website Redesign 3
... OMRON HEALTHCARE Co., Ltd., a,subsidiary of Omron ... home,healthcare, and wellness products, has developed the ... release worldwide in,spring 2009., "HEM-SOLAR monitors ... blood pressure readings wherever sunlight is available," ...
... Renew Acclaimed Series, NEW YORK, March 12 ... of Life" are being inundated with calls,blogs, e-mails, faxes ... renewed. These are not just ordinary fans. Many of ... survivors who are not,used to giving up a fight. ...
... watch TVs or computers, study finds , , WEDNESDAY, March 12 ... far too many hours a week in front of TVs ... "screen time." , "The take-home message is that we have ... healthier alternatives in their neighborhoods," said study author Tracie A. ...
... 12 The Providence,Service Corporation (Nasdaq: PRSC ) ... statement for shares of its common stock on Form ... anticipates,that it will file the proposed shelf registration statement ... 10-K for the Year Ended,December 31, 2007; however, it ...
... the Johns Hopkins Kimmel Cancer Center have uncovered,clearly recognizable ... early-stage lung cancers that look like good,predictors of which ... The discovery, they say, could change the approach to ... a pea - which are known to recur,within five ...
... Do you remember the seventh song that played on ... us dont, thanks to a normal forgetting process that is ... Researchers at the Buck Institute now believe that this normal ... this effect is key to the profound memory loss associated ...
Cached Medicine News:Health News:Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors 2Health News:Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors 3Health News:Cancer Survivors Lobby Lifetime TV to Order More of 'Side Order of Life' 2Health News:Teens Spending Too Much Screen Time 2Health News:Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement 2Health News:DNA detectives find genetic markers for lung cancers most likely to recur 2Health News:Paradoxical Alzheimer's finding may shed new light on memory loss 2
The 81483N projector operates off of DC power for maximum portability. The 20 watt halogen bulb with a specially designed reflector provides maximum brightness and portability....
Integrated electronics, single-chip CCD camera with PAL and NTSC output. PAL output at 460 lines, NTSC output at 470 lines, focal length 30mm. 90mm length x 20mm diameter....
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
Medicine Products: